Details for New Drug Application (NDA): 206318
✉ Email this page to a colleague
The generic ingredient in RIVASTIGMINE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.
Summary for 206318
Tradename: | RIVASTIGMINE |
Applicant: | Zydus Pharms |
Ingredient: | rivastigmine |
Patents: | 0 |
Pharmacology for NDA: 206318
Mechanism of Action | Cholinesterase Inhibitors |
Medical Subject Heading (MeSH) Categories for 206318
Suppliers and Packaging for NDA: 206318
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RIVASTIGMINE | rivastigmine | FILM, EXTENDED RELEASE;TRANSDERMAL | 206318 | ANDA | Northstar Rx LLC. | 16714-115 | 16714-115-02 | 30 POUCH in 1 CARTON (16714-115-02) / 24 h in 1 POUCH (16714-115-01) |
RIVASTIGMINE | rivastigmine | FILM, EXTENDED RELEASE;TRANSDERMAL | 206318 | ANDA | Northstar Rx LLC. | 16714-116 | 16714-116-02 | 30 POUCH in 1 CARTON (16714-116-02) / 24 h in 1 POUCH (16714-116-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | FILM, EXTENDED RELEASE;TRANSDERMAL | Strength | 4.6MG/24HR | ||||
Approval Date: | Mar 4, 2019 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | FILM, EXTENDED RELEASE;TRANSDERMAL | Strength | 9.5MG/24HR | ||||
Approval Date: | Mar 4, 2019 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | FILM, EXTENDED RELEASE;TRANSDERMAL | Strength | 13.3MG/24HR | ||||
Approval Date: | Mar 4, 2019 | TE: | AB | RLD: | No |
Complete Access Available with Subscription